Description:

CALGB 90601: Follow-Up Form Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer NCT00942331 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=6591C082-D8C1-EC1C-E040-BB89AD43479B

Link:

https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=6591C082-D8C1-EC1C-E040-BB89AD43479B

Keywords:
Versions (2) ▾
  1. 8/26/12
  2. 1/8/15
Uploaded on:

January 8, 2015

DOI:
No DOI assigned. To request one pleaselog in.
License:
Creative Commons BY-NC 3.0 Legacy
Model comments:

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for:

Item comments for:

In order to download data models you must be logged in. Please log in or register for free.

Follow-Up Form Bladder Cancer (NCT00942331)

Details

No Instruction available.

  1. StudyEvent: CALGB 90601: Follow-Up Form
    1. No Instruction available.
Are data amended
Vital Status
Patient's Vital Status
Primary Cause of Death
Performance Status
Kg
Treatment Status
Treatment Status (Mark one with an X)
Disease Follow-up Status
Has the patient had a documented clinical assessment for this cancer? (since submission of the previous follow-up form)
Measurable Disease Response
Response Status at This Assessment
Sites of Progression
5 more items in the detailed view.
Notice Of New Primary
Has a new primary cancer or MDS been diagnosed that has not been previously reported?
Long-term Toxicity
Has the patient experienced post diagnosis of progression or new primary, any severe (Grade > 3), long-term toxicity that has not been previously reported
Non-protocol Therapy
Has the patient received any non-protocol cancer therapy during this reporting period?
Specify (If yes,)
Back to the top of the page